Mergers & Antitrust Law News

Agilent Makes Immunotherapy Bet With $1.17 Billion Biotek Deal

July 11, 2019, 2:13 PM

Agilent Technologies Inc. agreed to buy closely held BioTek Instruments Inc. for $1.17 billion, in a deal designed to capitalize on a push by big pharmaceutical companies to develop new drugs that harness the immune system to fight cancer.

Santa Clara, Calif.-based Agilent makes instruments and software and provides services to drugmakers in the process of developing new therapies. BioTek, based in Winooski, Vt., focuses on cell-imaging systems that allow companies to see how therapies work in real time.

“This is an area of research that’s been really fast growing and is providing great new insights to researchers in the...

To read the full article log in. To learn more about a subscription click here.